AIM ImmunoTech (AIM) Change in Receivables (2017 - 2024)
AIM ImmunoTech's (AIM) quarterly Change in Receivables came in at -$3000.0 in Q4 2024, down 100.25% YoY from $1.2 million in Q1 2024, and down 200.0% on a QoQ basis from $3000.0 in Q2 2024.
AIM ImmunoTech (AIM) Change in Receivables (2017 - 2024) Analysis & Trends
AIM ImmunoTech (AIM) has 8 years of Change in Receivables data on file, last reported at -$3000.0 in Q4 2024.
- Quarterly Change in Receivables fell 100.25% year-over-year to -$3000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.2 million (down 141.81% YoY) and the FY2024 annual result came in at -$1.2 million, down 140.65% from the prior year.
- Change in Receivables slipped to -$3000.0 in Q4 2024, from $3000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.7 million in Q4 2022 to a low of -$1.2 million in Q1 2024.
- A 5-year average of $160800.0 and a median of -$4500.0 in 2020 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2020 — Change in Receivables tumbled 101.8% — and 2022, when it jumped 6085.71%.
- Tracing AIM's Change in Receivables over 5 years: stood at -$22000.0 in 2020, then decreased by 27.27% to -$28000.0 in 2021, then jumped by 6085.71% to $1.7 million in 2022, then decreased by 29.36% to $1.2 million in 2023, then sank by 100.25% to -$3000.0 in 2024.
- The last three Change in Receivables figures came in at -$3000.0 (Q4 2024), $3000.0 (Q2 2024), and -$1.2 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | - |
| 10 | AIM ImmunoTech | 4.51 Mn | -5.45 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -1.18 Mn |
| Mar 31, 2024 | -1.18 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | -28,000.00 |
| Dec 31, 2021 | -28,000.00 |
| Dec 31, 2020 | -22,000.00 |
| Dec 31, 2020 | -22,000.00 |
| Sep 30, 2020 | -14,000.00 |
| Sep 30, 2020 | -14,000.00 |
| Jun 30, 2020 | -6,000.00 |
| Jun 30, 2020 | -6,000.00 |
| Mar 31, 2020 | 2,000.00 |
| Mar 31, 2020 | 2,000.00 |